gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · URGNHealthcarePharmaceuticals

UroGen Pharma Ltd. Ordinary Shares (URGN)

$28.74−16.45%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$28.74▲ 45.08% in range
Nov 4, 2025Low $17.00 · High $50.29Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

UroGen Pharma closed at $28.74 on Nov 4, down 16.45%, 42.9% below its 52-week closing high. Volume of 2.9M shares was 2.43× its 20-day average (well above normal).

Split-adjusted performance: -30.6% over one month, +9.5% over six months, +39.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $72.46M, up 199.2% from a year earlier, with a net margin of -19.8%.

Short interest was 5.6M shares at the Oct 15 settlement, down 27.8% from the prior report (12.3% of float, 4.9 days to cover).

Market cap$1.40B48.9M shares
Revenue · quarter$72.5M+199.2% YoY
Diluted EPS$-0.28—
P/E · TTM—P/S 7.4×
Net margin-19.8%Gross 90.9%
Dividend yieldNone
52-week range17.00 – 50.29−42.9% from high
Volume2.9M2.43× 20-day avg
Volatility · 60d54.9%Annualised
Short % of float12.3%4.9 days to cover
Net cash-$85.1MCash $108.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −14.8%1M −30.6%3M −37.0%6M +9.5%YTD +22.7%1Y +39.4%3Y +164.4%5Y +76.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum76
Revenue growth89
Net margin56
Value (low P/E)—
Size74

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.6M−27.8% vs prior
Days to cover4.9Settled Oct 15
% of float12.3%
Short vol. 10d62.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
URGNUroGen Pharma$28.74−16.45%+9.5%+199.2%−19.8%—$1.40B
DMRADamora Therapeutics$22.94+3.89%————$1.42BCompare
KRSAKorsana Biosciences$30.56−4.38%————$1.39BCompare
ANABAnaptysBio$47.51−0.46%−29.5%−8.0%−206.9%—$1.42BCompare
ETONEton Pharmaceutcials$50.72−0.45%+68.2%+98.6%30.8%114.3$1.45BCompare
PCRXPacira BioSciences$36.40+0.03%+53.7%+6.2%2.4%99.2$1.45BCompare
KARDKardigan$15.56+8.66%————$1.45BCompare
RAPPRapport Therapeutics$25.93+1.93%−30.0%———$1.46BCompare
TYRATyra Biosciences$21.53+0.73%−36.3%———$1.48BCompare

News about UroGen Pharma

All news →
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 16h ago▼ NegativeUroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerGlobeNewswire Inc. · 2d ago▲ PositiveUroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026GlobeNewswire Inc. · Oct 27, 2026NeutralHere's Why You Should Add URGN Stock to Your Portfolio NowZacks Investment Research · Sep 30, 2026▲ PositiveUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Sep 4, 2026▲ Positive

Quick answers

What does UroGen Pharma do?
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release.
What is URGN's market cap?
$1.40B, based on the Nov 4 close of $28.74.
Does UroGen Pharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of URGN is sold short?
5.6M shares, 12.3% of float, as of Oct 15, 2026.
What sector is URGN in?
Healthcare, in the Pharmaceuticals industry.

About UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

HQ: Ra'Anana, L3291 employeesListed May 4, 2017urogen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology